Vontobel Holding Ltd. Boosts Stake in Boston Scientific Co. (NYSE:BSX)

Vontobel Holding Ltd. increased its stake in shares of Boston Scientific Co. (NYSE:BSX - Free Report) by 2.7% in the fourth quarter, according to its most recent 13F filing with the SEC. The firm owned 990,738 shares of the medical equipment provider's stock after purchasing an additional 26,005 shares during the period. Vontobel Holding Ltd. owned approximately 0.07% of Boston Scientific worth $57,275,000 at the end of the most recent reporting period.

A number of other hedge funds have also recently made changes to their positions in the stock. Bruce G. Allen Investments LLC acquired a new stake in shares of Boston Scientific in the 4th quarter valued at $28,000. Sunbelt Securities Inc. acquired a new stake in shares of Boston Scientific in the 1st quarter valued at $32,000. Motco raised its holdings in shares of Boston Scientific by 136.3% in the 3rd quarter. Motco now owns 645 shares of the medical equipment provider's stock valued at $34,000 after purchasing an additional 372 shares in the last quarter. Venturi Wealth Management LLC raised its holdings in shares of Boston Scientific by 58.0% in the 4th quarter. Venturi Wealth Management LLC now owns 586 shares of the medical equipment provider's stock valued at $34,000 after purchasing an additional 215 shares in the last quarter. Finally, Coppell Advisory Solutions LLC acquired a new stake in Boston Scientific during the 2nd quarter worth $34,000. Hedge funds and other institutional investors own 89.07% of the company's stock.

Wall Street Analyst Weigh In

Several equities research analysts recently commented on the stock. Needham & Company LLC lifted their price target on shares of Boston Scientific from $60.00 to $71.00 and gave the stock a "buy" rating in a research note on Thursday, February 1st. Argus lifted their price target on shares of Boston Scientific from $69.00 to $80.00 and gave the stock a "buy" rating in a research note on Wednesday, April 3rd. Royal Bank of Canada lifted their price target on shares of Boston Scientific from $70.00 to $78.00 and gave the stock an "outperform" rating in a research note on Monday. Citigroup lifted their price target on shares of Boston Scientific from $71.00 to $79.00 and gave the stock a "buy" rating in a research note on Wednesday, April 3rd. Finally, JPMorgan Chase & Co. raised their price objective on shares of Boston Scientific from $60.00 to $72.00 and gave the stock an "overweight" rating in a research report on Thursday, February 1st. Two equities research analysts have rated the stock with a hold rating, eighteen have given a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and a consensus target price of $68.50.

Boston Scientific Stock Down 0.9 %

Shares of BSX stock traded down $0.63 on Monday, hitting $67.44. The stock had a trading volume of 6,526,779 shares, compared to its average volume of 6,374,410. The firm has a market capitalization of $98.94 billion, a price-to-earnings ratio of 63.13, a P/E/G ratio of 2.38 and a beta of 0.78. The stock's 50 day moving average is $66.99 and its 200-day moving average is $59.42. The company has a debt-to-equity ratio of 0.44, a quick ratio of 0.82 and a current ratio of 1.32. Boston Scientific Co. has a 52-week low of $48.35 and a 52-week high of $69.21.

Boston Scientific (NYSE:BSX - Get Free Report) last announced its earnings results on Wednesday, January 31st. The medical equipment provider reported $0.55 earnings per share for the quarter, beating the consensus estimate of $0.51 by $0.04. The business had revenue of $3.73 billion during the quarter, compared to the consensus estimate of $3.59 billion. Boston Scientific had a net margin of 11.19% and a return on equity of 15.99%. During the same period in the prior year, the firm earned $0.45 earnings per share. As a group, research analysts expect that Boston Scientific Co. will post 2.25 earnings per share for the current year.

Insider Activity at Boston Scientific

In related news, EVP Wendy Carruthers sold 6,983 shares of the company's stock in a transaction on Friday, February 23rd. The shares were sold at an average price of $66.89, for a total value of $467,092.87. Following the sale, the executive vice president now directly owns 56,508 shares of the company's stock, valued at $3,779,820.12. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. In related news, EVP Wendy Carruthers sold 6,983 shares of the company's stock in a transaction on Friday, February 23rd. The shares were sold at an average price of $66.89, for a total value of $467,092.87. Following the sale, the executive vice president now directly owns 56,508 shares of the company's stock, valued at $3,779,820.12. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Edward J. Ludwig sold 7,000 shares of the company's stock in a transaction on Tuesday, February 13th. The shares were sold at an average price of $65.03, for a total transaction of $455,210.00. Following the completion of the sale, the director now directly owns 41,374 shares in the company, valued at $2,690,551.22. The disclosure for this sale can be found here. Insiders have sold 50,979 shares of company stock valued at $3,418,529 over the last ninety days. Corporate insiders own 0.50% of the company's stock.

About Boston Scientific

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.